Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 559-573

  Backus, L I ^a   Belperio, P S ^a   Shahoumian, T A ^a   Loomis, T P ^a   Mole, L A ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG RESPONSE; ETHNICITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; OBSERVATIONAL STUDY; PATIENT HISTORY OF THERAPY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VETERAN; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VETERANS;

EID: 84938552800     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13300     Document Type: Article

References (21)

1. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA,. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
2. Hézode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme (ANRS CO20-CUPIC) -NCT01514890. J Hepatol 2013; 59: 434-41.
3. Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM,. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 2014; 59: 3043-52.
4. Gordon SC, Muir AJ, Lim JK, et al,. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCVTARGET. J Hepatol 2015; 62: 286-93.
5. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
6. Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA,. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm 2014; 20: 533-40.
7. Backus LI, Gavrilov S, Loomis TP, et al,. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16: 775-83.
8. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2007; 43: 1317-25.
9. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
10. Chou R, Wasson N,. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807-20.
11. Ioannou GN, Beste LA, Green PK,. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection, based on a nationwide study of Veterans. Clin Gastroenterol Hepatol 2014; 12: 1371-80.
12. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87.
13. Miller MH, Agarwal K, Austin A, et al,. Review article: 2014 UK consensus guidelines-hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39: 1363-75.
14. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
15. Pearlman BL, Ehleben C, Perrys M,. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis c-related child's class a cirrhosis. Gastroenterology 2015; 148: 762-70.
16. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
17. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
18. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org (accessed June 8, 2015).
19. Brennan TA, Lotvin A, Shrank W,. Analysis of 'real-world' sofosbuvir use and discontinuation rates. CVS Health. August 2014. Available at: http://www.cvshealth.com/sites/default/files/hepatitisCutilization.pdf (accessed December 15, 2014).
20. Stattermayer AF, Scherzer T, Beinhardt S, et al,. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014; 39: 1059-70.
21. Covolo L, Bibert S, Donato F, et al,. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 2014; 39: 322-30.